Alexium receives US EPA approval for Alexiflam® NF

|

Published 24-APR-2019 10:25 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Alexium International Group Ltd (ASX:AJX, NASDAQ:AXXIY) has received US Environmental Protection Agency (EPA) approval under TSCA (Toxic Substance Control Act) for the manufacture and sale of Alexiflam® NF in the US.

The EPA approval provides Alexium with access to the largest market region for flame retardant cotton and follows the recently negotiated Memorandum of Understanding with ICL (TASE/NYSE: ICL) for the future manufacture, marketing and sales of Alexiflam® NF.

Alexiflam® NF is a patent pending flame retardant developed by Alexium for the treatment of cotton and cellulose-based textiles.

Alexiflam® NF has enhanced flame-retardant properties over incumbent products, and it also provides a number of improved environmental and health advantages.

These include the product being essentially formaldehyde free, as well as featuring an ammoniation free application.

Alexium to meet military and industrial sales targets

The approval received under the US Toxic Substances Control Act (TSCA) follows the successful completion of the EPA’s risk assessment of the hazards associated with the manufacturing, processing, and use of Alexiflam® NF.

TSCA regulates the introduction of new chemical products in the US, and its stringent expectations work in favour of Alexium, effectively providing reasonable barriers to entry in relation to potential competitors.

Recently updated by the Lautenberg Chemical Safety Act, the assessment of Alexiflam® NF was under the more rigorous new TSCA standard.

This EPA approval provides Alexium with the ability to manufacture and sell Alexiflam® NF in the US, which represents nearly half of the global flame-retardant cotton market.

Based on the provisions of the approval, Alexium can produce the volumes of Alexiflam® NF needed to support the company’s sales targets for military and industrial application in the US.

Alexium can now focus on commercialisation

Commenting on the EPA’s approval of Alexiflam NF®, Alexium chief executive Bob Brookins said, “EPA approval of Alexiflam® NF marks a significant milestone for the company.

“This approval supports Alexium’s manufacture and sales into the US, which represents the largest global market for flame retardant cotton products.

“The EPA approval builds on our recent MoU with ICL for them to act as the future manufacturer and distributor of Alexiflam® NF.”

The prior consolidation of the arrangement with ICL makes this development all the more significant as it leaves Alexium well placed to drive the commercialisation of Alexiflam® NF, delivering on the extensive global sales opportunities for the unique textile technology.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X